057 Novel Chimeric Immunoreceptors for Pemphigus Vulgaris (PV) Therapy
C. Ellebrecht,V. Bhoj,A. Nace,E. Choi,M. Cho,X. Mao,J. Seykora,G. Cotsarelis,M. Milone,A. Payne
DOI: https://doi.org/10.1016/j.jid.2016.02.082
IF: 7.59
2016-01-01
Journal of Investigative Dermatology
Abstract:PV therapy relies on chronic immunosuppression, which causes significant morbidity and mortality. Ideal therapy targets only pathogenic autoimmune cells while sparing protective immunity. Alternatively, complete but transient B cell depletion should cure PV, since novel autoreactive clones are not detected upon generation of a new B cell repertoire. To achieve these goals, we tested 2 immunotherapy strategies. For targeted therapy, we designed chimeric autoantibody receptors (CAARs), consisting of the extracellular domains of the PV autoantigen, desmoglein (Dsg) 3, fused to T cell cytoplasmic signaling domains. CAARs direct human T cells to specifically kill anti-Dsg3 IgG+ B cells both in vitro and in vivo in a PV mouse model (n=61, p<0.001). Polyclonal PV IgG cause CAAR-T cell proliferation, and anti-Dsg3 mAbs do not prevent or can stimulate CAAR-T cytotoxicity correlating with their kinetic off-rate, suggesting that soluble autoAbs promote CAAR efficacy in vivo. To investigate safety in vivo, we injected CAAR-T cells in human skin xenografted mice. CAARs cause no epidermal toxicity compared to a control immunoreceptor (n=6, p=0.99) that has shown no skin toxicity in human leukemia clinical trials. No toxicity to desmosome-bearing tissues such as heart, lung, gut, kidney and liver was observed. Blood counts of Fcγ-receptor+ monocytes and neutrophils, which bind anti-Dsg3 IgG, are unaffected by CAAR therapy (n=24, p=0.46-0.71). These data indicate that Dsg3 CAAR-T cells are highly specific and effective in targeting autoimmune B cells in PV. For complete, transient B cell depletion, we designed a pan B-cell chimeric antigen receptor, co-expressed with an inducible caspase 9 “suicide” gene (sCAR). sCAR-T cells effectively deplete CD19+ B cells in an in vivo model (n=12, p<0.001). Induced activation of caspase 9 results in efficient in vitro depletion of >99% of sCAR-T cells, showing the feasibility of this approach. In summary, we have validated 2 novel, non-redundant strategies for adoptive immunotherapy of PV, which can be applied to other autoimmune diseases.